271 related articles for article (PubMed ID: 37531032)
1. A Brief Review of Gepants.
Li D; Abreu J; Tepper SJ
Curr Pain Headache Rep; 2023 Sep; 27(9):479-488. PubMed ID: 37531032
[TBL] [Abstract][Full Text] [Related]
2. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?
Moreno-Ajona D; Pérez-Rodríguez A; Goadsby PJ
Curr Opin Neurol; 2020 Jun; 33(3):309-315. PubMed ID: 32251023
[TBL] [Abstract][Full Text] [Related]
3. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
4. Ubrogepant for the treatment of migraine.
Curto M; Capi M; Cipolla F; Cisale GY; Martelletti P; Lionetto L
Expert Opin Pharmacother; 2020 May; 21(7):755-759. PubMed ID: 32011192
[TBL] [Abstract][Full Text] [Related]
5. Raynaud's phenomenon associated with calcitonin gene-related peptide receptor antagonists case report.
Bedrin K; Ailani J; Dougherty C
Headache; 2022 Nov; 62(10):1419-1423. PubMed ID: 36426766
[TBL] [Abstract][Full Text] [Related]
6. CGRP receptor antagonists (gepants).
Younis S; Latysheva NV; Danilov AB; Ashina M
Handb Clin Neurol; 2024; 199():51-66. PubMed ID: 38307667
[TBL] [Abstract][Full Text] [Related]
7. The pharmacotherapeutic management of episodic and chronic migraine with gepants.
Tajti J; Szok D; Csáti A; Vécsei L
Expert Opin Pharmacother; 2023 Jun; 24(8):947-958. PubMed ID: 37038933
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
Porreca F; Navratilova E; Hirman J; van den Brink AM; Lipton RB; Dodick DW
Cephalalgia; 2024 Mar; 44(3):3331024241238153. PubMed ID: 38477313
[TBL] [Abstract][Full Text] [Related]
9. Gepants - a long way to cure: a narrative review.
Altamura C; Brunelli N; Marcosano M; Fofi L; Vernieri F
Neurol Sci; 2022 Sep; 43(9):5697-5708. PubMed ID: 35650458
[TBL] [Abstract][Full Text] [Related]
10. Update of Gepants in the Treatment of Chronic Migraine.
Cho S; Kim BK
Curr Pain Headache Rep; 2023 Oct; 27(10):561-569. PubMed ID: 37656319
[TBL] [Abstract][Full Text] [Related]
11. Focus on zavegepant: the first intranasal third-generation gepant.
Scuteri D; Tarsitano A; Tonin P; Bagetta G; Corasaniti MT
Pain Manag; 2022 Nov; 12(8):879-885. PubMed ID: 36189708
[TBL] [Abstract][Full Text] [Related]
12. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
Chiang CC; Schwedt TJ
Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
[TBL] [Abstract][Full Text] [Related]
13. Gepants for the treatment of migraine.
Negro A; Martelletti P
Expert Opin Investig Drugs; 2019 Jun; 28(6):555-567. PubMed ID: 31081399
[TBL] [Abstract][Full Text] [Related]
14. Ubrogepant to treat migraine.
Dhir A
Drugs Today (Barc); 2020 Jul; 56(7):459-467. PubMed ID: 32648856
[TBL] [Abstract][Full Text] [Related]
15. A systematic review with expert opinion on the role of gepants for the preventive and abortive treatment of migraine.
Argyriou AA; Mantovani E; Mitsikostas DD; Vikelis M; Tamburin S
Expert Rev Neurother; 2022 Jun; 22(6):469-488. PubMed ID: 35707907
[TBL] [Abstract][Full Text] [Related]
16. Preventive Treatment of Migraine.
Lipton RB
Continuum (Minneap Minn); 2024 Apr; 30(2):364-378. PubMed ID: 38568488
[TBL] [Abstract][Full Text] [Related]
17. Real world considerations for newly approved CGRP receptor antagonists in migraine care.
Scuteri D; Tonin P; Nicotera P; Bagetta G; Corasaniti MT
Expert Rev Neurother; 2022 Mar; 22(3):221-230. PubMed ID: 35240905
[TBL] [Abstract][Full Text] [Related]
18. Atogepant: an emerging treatment for migraine.
Rustichelli C; Avallone R; Ferrari A
Expert Opin Pharmacother; 2022 Apr; 23(6):653-662. PubMed ID: 35319319
[TBL] [Abstract][Full Text] [Related]
19. Gepants for Acute and Preventive Migraine Treatment: A Narrative Review.
Rissardo JP; Caprara ALF
Brain Sci; 2022 Nov; 12(12):. PubMed ID: 36552072
[TBL] [Abstract][Full Text] [Related]
20. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
